Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 19.56% is in line with its 5-year average of 21.48%, near the low end of its 5-year range (18.67%–26.09%).
As of the fiscal period ended Friday, July 31, 2026. 1.26% above its 12-month average of 19.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
19.56%
RETURN ON EQUITY (ROE) AVG TTM
19.31%
RETURN ON EQUITY (ROE) AVG 3Y
19.99%
RETURN ON EQUITY (ROE) AVG 5Y
21.48%
RETURN ON EQUITY (ROE) AVG 10Y
17.88%
RETURN ON EQUITY (ROE) AVG 15Y
17.23%
RETURN ON EQUITY (ROE) AVG 20Y
17.52%
CURRENT VS TTM AVG
+1.26%
CURRENT VS 3Y AVG
-2.16%
CURRENT VS 5Y AVG
-8.94%
CURRENT VS 10Y AVG
+9.39%
CURRENT VS 15Y AVG
+13.49%
CURRENT VS 20Y AVG
+11.62%
SECTOR MEDIAN · HEALTHCARE
13.25%
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+47.60%
vs the sector median at left
Agilent Technologies, Inc.
Market Cap
$41.48B
Return on Equity (ROE)
19.56%
TTM Avg
19.31%
3Y Avg
19.99%
5Y Avg
21.48%
Market Cap
$41.04B
Return on Equity (ROE)
70.67%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$42.67B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$42.81B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$34.80B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$49.35B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$49.93B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | $41.48B | 19.56% | 19.31% | 19.99% | 21.48% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.04B | 70.67% | 60.82% | 72.53% | 81.69% |
| IQVIA Holdings Inc. (IQV)vs › | $42.67B | 22.28% | 21.77% | 21.17% | 17.55% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.81B | 9.10% | -6.34% | -12.86% | -14.53% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.80B | 59.67% | -187.43% | 134.89% | 51.69% |
| Humana Inc. (HUM)vs › | $48.40B | 6.65% | 7.05% | 11.93% | 15.09% |
| Alcon Inc. (ALC)vs › | $33.71B | 2.96% | 4.58% | 3.90% | 2.45% |
| Becton, Dickinson and Company (BDX)vs › | $49.35B | 3.85% | 6.60% | 6.50% | 6.42% |
| Edwards Lifesciences Corporation (EW)vs › | $49.93B | 9.46% | 26.07% | 24.86% | 23.86% |
| ResMed Inc. (RMD)vs › | $32.06B | 23.13% | 23.30% | 22.33% | 21.49% |
ROE
19.6%
ROA
10.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | 19.56% |
| 2026-04-30 | 19.85% |
| 2026-01-31 | 18.67% |
| 2025-10-31 | 19.33% |
| 2025-07-31 | 19.15% |
| 2025-04-30 | 19.00% |
| 2025-01-31 | 20.89% |
| 2024-10-31 | 21.85% |
| 2024-07-31 | 23.94% |
| 2024-04-30 | 19.99% |
| 2024-01-31 | 19.97% |
| 2023-10-31 | 21.21% |
| 2023-07-31 | 20.39% |
| 2023-04-30 | 23.37% |
| 2023-01-31 | 23.59% |
| 2022-10-31 | 23.64% |
| 2022-07-31 | 26.09% |
| 2022-04-30 | 24.66% |
| 2022-01-31 | 23.38% |
| 2021-10-31 | 22.45% |
| 2021-07-31 | 20.02% |
| 2021-04-30 | 19.23% |
| 2021-01-31 | 16.86% |
| 2020-10-31 | 14.75% |
| 2020-07-31 | 13.87% |
| 2020-04-30 | 14.32% |
| 2020-01-31 | 15.76% |
| 2019-10-31 | 22.56% |
| 2019-07-31 | 22.58% |
| 2019-04-30 | 21.80% |
| 2019-01-31 | 22.64% |
| 2018-10-31 | 6.92% |
| 2018-07-31 | 6.53% |
| 2018-04-30 | 5.14% |
| 2018-01-31 | 4.33% |
| 2017-10-31 | 14.17% |
| 2017-07-31 | 13.69% |
| 2017-04-30 | 13.27% |
| 2017-01-31 | 11.80% |
| 2016-10-31 | 10.85% |
| 2016-07-31 | 10.96% |
| 2016-04-30 | 11.12% |
| 2016-01-31 | 11.35% |
| 2015-10-31 | 9.65% |
| 2015-07-31 | 8.02% |
| 2015-04-30 | 8.78% |
| 2015-01-31 | 9.84% |
| 2014-10-31 | 10.36% |
| 2014-07-31 | 12.28% |
| 2014-04-30 | 12.65% |
| 2014-01-31 | 13.59% |
| 2013-10-31 | 13.70% |
| 2013-07-31 | 19.59% |
| 2013-04-30 | 19.10% |
| 2013-01-31 | 20.61% |
| 2012-10-31 | 22.25% |
| 2012-07-31 | 20.88% |
| 2012-04-30 | 23.38% |
| 2012-01-31 | 23.33% |
| 2011-10-31 | 23.49% |
| 2011-07-31 | 24.21% |
| 2011-04-30 | 22.51% |
| 2011-01-31 | 23.95% |
| 2010-10-31 | 21.19% |
| 2010-07-31 | 14.88% |
| 2010-04-30 | 7.36% |
| 2010-01-31 | -0.62% |
| 2009-10-31 | -1.24% |
| 2009-07-31 | 7.03% |
| 2009-04-30 | 15.01% |
| 2009-01-31 | 24.78% |
| 2008-10-31 | 27.08% |
| 2008-07-31 | 20.16% |
| 2008-04-30 | 20.85% |
| 2008-01-31 | 19.16% |
| 2007-10-31 | 19.73% |
| 2007-07-31 | 18.46% |
| 2007-04-30 | 18.26% |
| 2007-01-31 | 17.53% |
| 2006-10-31 | 90.65% |
| 2006-07-31 | 83.94% |
| 2006-04-30 | 75.11% |
| 2006-01-31 | 72.69% |
| 2005-10-31 | 8.01% |
| 2005-07-31 | 9.52% |
| 2005-04-30 | 9.61% |
| 2005-01-31 | 10.11% |
| 2004-10-31 | 9.78% |
| 2004-07-31 | 8.65% |
| 2004-04-30 | -42.92% |
| 2004-01-31 | -52.72% |
| 2003-10-31 | -72.88% |
| 2003-07-31 | -84.82% |
